Background {#Sec1}
==========

Preeclampsia is a major public health problem due to its frequency as well as its related maternal and perinatal morbidity and mortality, with a prevalence of 4.6% among pregnant women worldwide \[[@CR1]\]. It is not only associated with adverse pregnant outcomes, but also contribute to higher risk of cardiovascular diseases, renal failure, type 2 diabetes mellitus, hypothyroidism and cognitive defects in future \[[@CR2]\]. Furthermore, children born from preeclamptic pregnancies are more prone to hypertension, insulin resistance and diabetes mellitus, neurological complications, stroke, and mental disorders in their later lives \[[@CR2]\].

Thyroid dysfunction is common among pregnant women. According to previous reports, the prevalence of clinical overt hyperthyroidism or subclinical hyperthyroidism is about 0.1--0.4% during pregnancy. The prevalence of hypothyroidism is about 2.5%, with clinical hypothyroidism accounting for 0.2--0.3%, and subclinical hypothyroidism for 2--3% \[[@CR3], [@CR4]\], while hypothyroxinemia for 1--2% \[[@CR5]\]. According to domestic reports in China, the prevalence of gestational clinical hypothyroidism is approximately 0.5--0.6%, with subclinical hypothyroidism 2--3%, and hypothyroxinemia 1.6%. The prevalence of subclinical hypothyroidism is the highest.

Hypothyroidism is known to be one of the causes of hypertension \[[@CR6]\]. Both untreated subclinical hypothyroidism and overt hypothyroidism are associated with multiple adverse outcomes in the mother and fetus \[[@CR3], [@CR7]--[@CR23]\]. Women with treated hypothyroid diseases are not at higher risk than healthy pregnant women for adverse neonatal outcomes, but may also be at increased risk for preeclampsia \[[@CR24]\]. However, Casey et al*.* do not find any increased incidence of preeclampsia in subclinical hypothyroid women \[[@CR3]\]. Medici M et al. \[[@CR25]\] have found that biochemical hyperthyroidism but not hypothyroidism during early pregnancy is associated with an increased risk of hypertensive disorders.

Therefore, the relationships between thyroid dysfunction and pregnancy outcomes in preeclampsia still needs to be clarified. It is known that the placental dysfunction is more likely to occur in the early onset preeclampsia at \< 34 weeks of gestation \[[@CR26], [@CR27]\] and early onset preeclampsia conferred a substantially higher risk of cardiovascular \[[@CR28]\], respiratory, central nervous system, renal, hepatic, and other morbidity \[[@CR29]\]. However, in most previous studies, thyroid hormones were measured before 20 weeks of pregnancy. Associations of thyroid hormones measured in the second half of pregnancy in different subtypes of preeclampsia (mild and severe preeclamptic women as well as early onset and late onset women) and neonatal outcomes of pregnancy (rates of preterm birth and low neonatal birth weight) remained unclear and were investigated in the study.

Patients and methods {#Sec2}
====================

Study subjects {#Sec3}
--------------

This was a retrospective case-control study. Overall, 135 singleton pregnant women who developed gestational hypertension disease and their offspring delivered in Renmin Hospital of Wuhan University from January 2015 to June 2017 were consecutively enrolled in the study. All the data were collected from the electronic medical record system, such as age, gestational age, prenatal examination, neonatal information and neonatal complications, etc. Blood routine, hepatic and renal functions, blood glucose, blood lipid, coagulation function and thyroid functions were all performed at the laboratory department of our hospital during hospitalization in the second half trimester of pregnancy. The primary outcomes were the maternal and fetal complications, i.e. preterm birth and low birth weight. The Ethics Committee of Renmin Hospital of Wuhan University approved the study (in accordance with the Helsinki declaration). Inclusion criteria: 1. maternal age between 20 and 40 years old; 2. no chronic diseases before pregnancy, such as chronic hypertension, cardiovascular and cerebrovascular diseases, autoimmune diseases (SLE etc.), thrombotic diseases, diabetes, thyroid endocrine diseases, hepatic and renal diseases, mental diseases, etc.; 3. it was a singleton pregnancy; 4. adequate iodine intake in daily diet; 5. delivered in our hospital. Exclusion criteria: 1. pregnant women with history of thyroid related diseases before pregnancy and taking medicines for thyroid diseases; 2. pregnant women with unhealthy diet habit; 3. pregnant women without follow-up; 4. pregnant women without results of thyroid function test; 5. pregnant women with diabetes or gestational diabetes or some other endocrine diseases. (Fig. [1](#Fig1){ref-type="fig"}. Flow chart and data processing). Fig. 1Flow chart and data processing

Definitions {#Sec4}
-----------

Women without pre-existing hypertension were classified as having pregnant induced hypertension (PIH) if they had a systolic blood pressure ≥ 140 mmHg and/ or diastolic blood pressure ≥ 90 mmHg on at least two occasions first occurring after 20 gestational weeks.

Preeclampsia was defined as gestational hypertension in combination with one or more of the following new-onset conditions: proteinuria (urinary protein dip sticks ≥1+ or ≥ 300 mg/24-h); other maternal organ dysfunction, including renal insufficiency, hepatic dysfunction, neurological complications, and hematological complications; and uteroplacental dysfunction \[[@CR30]\].

Preterm birth was defined if babies were born before 37 gestational weeks.

Low birth weight was defined as birth weight less than 2500 g.

According to the guidelines for the management of thyroid disorders during pregnancy and postpartum issued by the American thyroid association in 2017 \[[@CR31]\], the definitions of thyroid diseases are as follows:

Clinical hypothyroidism: a. serum thyrotropic hormone (TSH) \> 4 mIU/L, and serum free thyroxine (FT4) \< lower limit of normal reference b. serum TSH \> 10 mIU/L, with or without FT4 reduction.

Subclinical hypothyroidism: serum TSH \> 4 mIU/L but no more than 10 mIU/L, serum FT4 is within the reference range.

Hypothyroxinemia: serum FT4 \< the lower limit of normal reference value, and TSH is within the range of gestation-specific thyroid function reference value.

Gestational thyrotoxicosis: when TSH is less than 0.1 mIU/L, FT4 \> gestational specific value reference upper limit.

Hashimoto thyroiditis: serum thyroid peroxidase antibody (TPOAb) ≥ 40 mIU/L.

Serum TSH, FT4, free triiodothyronine (FT3) and TPOAb levels were measured using electrochemi-luminescence immunoassay (Cobas Elesys 601, Roche Diagnostics). The reference ranges of FT4 in our hospital is 0.89--1.8 ng/dL; the reference ranges of FT3 in our hospital is 2.3--4.2 pg/mL.

Groups {#Sec5}
------

Based on the severity of the preeclampsia, we classified the patients into three groups 1) pregnancy induced hypertension (PIH), 2) mild preeclampsia (MPE), PIH with urinary protein dip sticks ≥1+ or ≥ 300 mg/24-h, and 3) severe preeclampsia (SPE), MPE plus at least one additional adverse condition including systolic blood pressure ≥ 160 mmHg and/ or diastolic blood pressure ≥ 110 mmHg or urinary protein dip sticks ≥3+ or ≥ 5 g/24-h or other maternal organ dysfunction. According to the onset time of the preeclampsia, we classified the patients also into three groups a) PIH b) early onset preeclampsia (EPE), preeclampsia appearing before 34 gestational weeks, and c) late onset preeclampsia (LPE), preeclampsia appearing at or after 34 gestational weeks \[[@CR32]\]. The comparisons were among PIH, MPE and SPE, as well as among PIH, EPE and LPE.

Statistical analysis {#Sec6}
--------------------

The data were expressed as frequencies or percentages for categorical variables and as means and standard deviations for normally distributed continuous variables, or medians and interquartile ranges for non-normally distributed continuous variables. Differences between the groups were compared by the chi-square or Fisher's exact test for categorical variables and multiple comparisons in ANOVA or Kruskal Wallis Test for continuous variables. Associations between thyroid dysfunction, gestational hypertension disease and neonatal outcomes were assessed by using the logistic regression. Unadjusted and adjusted odds ratios (ORs, adjusted for age, gestational history, menstrual cycle, family history, history of gestational hypertension), as well as 95% confidence intervals (95%CIs) were calculated. *P* \< 0.05 was considered to indicate statistical significance, while *P* \< 0.017 was considered statistically significant for multiple comparisons in chi-square test and Kruskal Wallis Test. All calculations were performed using the SPSS Version 19.0.

Results {#Sec7}
=======

PIH, MPE, and SPE {#Sec8}
-----------------

Of the 135 patients, 30 were PIH, 20 were MPE, and 85 were SPE. There were 7 cases of fetal growth restriction (FGR), 3 cases of placental abruption and 2 cases of pleural effusion in these patients. All 7 cases of FGR, 2 cases of pleural effusion and 2 cases of placental abruption occurred in patients with SPE, while only one case of placental abruption was found in patients with MPE. Table [1](#Tab1){ref-type="table"} presents the clinical, biochemical markers and the incidences of adverse neonatal outcomes among PIH, MPE and SPE. One abortion, two induced labor and two fetal deaths were reported in the SPE group. The gestational week and neonatal birth weight were significantly lower, and the preterm birth rate was significantly higher in the SPE group than those in the other two groups (*P* \< 0.001). Thyroid dysfunction was more frequent in the SPE group than in the MPE group (*P* = 0.01). Brain natriuretic peptide (BNP) was significantly higher in the SPE group than that in the PIH group (*P* = 0.002). Table 1Comparisons of the clinical data from three groups of gestational hypertension according to the severity of the diseaseCharacteristicsPIH (*N* = 30)MPE (*N* = 20)SPE (*N* = 85)PIH vs. MPEPIH vs. SPEMPE vs. SPEAge (year, mean ± SD)30.43 ± 4.9931.65 ± 4.4431.45 ± 5.23*P* = 0.407*P* = 0.346*P* = 0.876Gestational weeks (at delivery) (week, mean ± SD)38.53 ± 1.5338.16 ± 2.3734.42 ± 4.13*P* = 0.899*P* \< 0.001*P* \< 0.001Sex of baby (male, n%)60.9% (14/23)50% (8/16)54.1% (40/74)*P* = 0.730*P* = 0.566*P* = 0.768Neonatal birth weight (g, mean ± SD)3192.41 ± 629.84(*N* = 29)3134.21 ± 720.14(*N* = 19)2356.06 ± 787.95(*N* = 71)*P* = 0.791*P* \< 0.001*P* \< 0.001Hematocrit (L/L, mean ± SD)0.38 ± 0.030.37 ± 0.020.37 ± 0.04*P* = 0.853*P* = 0.328*P* = 0.534Hemoglobin (g/L, mean ± SD)123.40 ± 9.36123.90 ± 8.43121.63 ± 14.41*P* = 0.892*P* = 0.514*P* = 0.474Platelet (10\^9/L, mean ± SD)220.53 ± 40.22204.90 ± 45.86194.38 ± 67.10*P* = 0.524*P* = 0.047*P* = 0.797Fibrinogen (g/L, mean ± SD)4.06 ± 0.743.93 ± 0.633.73 ± 0.81*P* = 0.575*P* = 0.052*P* = 0.301D-Dimer (mg/L, medians and interquartile ranges)1.67 (1.16--2.82)1.76 (1.07--2.97)1.84 (1.20--2.41)*P* = 0.823*P* = 0.607*P* = 0.877Brain natriuretic peptide (pg/mL, medians and interquartile ranges)26.50 (17.25--65.50)40 (21--90)84.5 (34.75--231.25)*P* = 0.265*P* = 0.002*P* = 0.075FT3 (pg/mL, medians and interquartile ranges)2.54 (2.24--2.69)2.65 (2.52--2.89)2.49 (2.26--2.70)*P* = 0.040*P* = 0.767*P* = 0.014FT4 (ng/dL, medians and interquartile ranges)0.98 (0.90--1.06)0.98 (0.86--1.06)0.93 (0.85--1.06)*P* = 0.992*P* = 0.286*P* = 0.311TSH (mIU/L, medians and interquartile ranges)2.32 (1.79--3.26)2.09 (1.65--2.96)2.58 (1.76--3.74)*P* = 0.342*P* = 0.881*P* = 0.361Triglyceride (mmol/L, medians and interquartile ranges)3.56 (2.78--5.93)4.15 (2.83--4.80)3.98 (2.85--4.94)*P* = 1.000*P* = 0.974*P* = 0.947Total cholesterol (mmol/L, mean ± SD)6.23 ± 1.065.25 ± 1.696.28 ± 1.75*P* = 0.150*P* = 0.998*P* = 0.121Low density lipoprotein (mmol/L, mean ± SD)2.92 ± 0.932.15 ± 1.082.72 ± 1.39*P* = 0.064*P* = 0.490*P* = 0.114High density lipoprotein (mmol/L, mean ± SD)1.95 ± 0.381.59 ± 0.731.76 ± 0.80*P* = 0.126*P* = 0.241*P* = 0.408Rate of preterm birth (n%)7.1% (2/28)15.8% (3/19)58.6% (41/70)*P* = 0.644*P* \< 0.001*P* = 0.001Rate of abortion (n%)001.3% (1/75)NSNSNSRate of induced labor (n%)002.7% (2/75)NSNSNSRate of fetal death (n%)002.7% (2/75)NSNSNSThyroid dysfunction (n%)60% (18/30)40% (8/20)70.6% (60/85)*P* = 0.166*P* = 0.286*P* = 0.010Hypothyroidism (n%)009.4% (8/85)NSNSNSSubclinical hypothyroidism (n%)20% (6/30)15% (3/20)11.8% (10/85)*P* = 0.748*P* = 0.622*P* = 0.988FT3 under the lower limit (n%)6.7% (2/30)08.2% (7/85)NS*P* = 0.847NSFT4 under the lower limit (n%)16.7% (5/30)20% (4/20)22.4% (19/85)*P* = 1.000*P* = 0.324*P* = 0.330FT3 and FT4 both under the lower limit (n%)6.7% (2/30)5% (1/20)9.4% (8/85)*P* = 1.000*P* = 0.709*P* = 0.517Hashimoto thyroiditis (n%)13.3% (4/30)10% (2/20)5.9% (5/85)*P* = 0.66*P* = 0.69*P* = 1hyperthyroidism (n%)003.5% (3/85)NSNSNSA nominal 2-sided probability value \< 0.05 was considered to indicate statistical significance, and adjustments were made for multiple comparisons in chi-square test and Kruskal Wallis Test (*P*~adjust~ \< 0.017)*PIH* pregnant induced hypertension; *MPE* mild preeclampsia; *SPE* severe preeclampsia; *FT3* free triiodothyronine; *FT4* free thyroxine; *TSH* thyrotropic hormone

PIH, EPE, and LPE {#Sec9}
-----------------

Table [2](#Tab2){ref-type="table"} shows the clinical, biochemical markers and the incidences of adverse neonatal outcomes among the PIH, EPE and LPE groups. There were 57 EPE and 48 LPE. One abortion and two induced labor were reported in the EPE group. Both EPE and LPE groups had one fetal death. There were 4 cases of FGR, 2 cases of placenta abruption and 2 cases of pleural effusion in the EPE group, 3 cases of FGR and one case of placenta abruption in the LPE group. BNP was significantly higher in the EPE group and in the LPE group than in the PIH group (*P* = 0.010, *P* = 0.005 respectively). The gestational week was significantly earlier, the neonatal birth weight was significantly lower, and the preterm birth rate was significantly higher in the EPE group compared with the other two groups (*P* \< 0.001). The EPE group also had the highest rate of thyroid dysfunction (71.9%). Table 2Comparisons of the clinical data from three groups of gestational hypertension according to the gestational ageCharacteristicsPIH (*N* = 30)EPE (*N* = 57)LPE (*N* = 48)PIH vs. EPEPIH vs. LPEEPE vs. LPEAge (year, mean ± SD)30.43 ± 4.9931.61 ± 5.3431.34 ± 4.78*P* = 0.304*P* = 0.445*P* = 0.785Gestational weeks (at delivery) (week, mean ± SD)38.53 ± 1.5332.70 ± 3.9538.01 ± 1.82*P* \< 0.001*P* = 0.454*P* \< 0.001Sex of baby (male, n%)60.9% (14/23)48.9% (23/47)58.1% (25/43)*P* = 0.348*P* = 0.830*P* = 0.382Neonatal birth weight (g, mean ± SD)3192.41 ± 629.84(*N* = 29)1989.09 ± 712.97(*N* = 44)3028.48 ± 591.00(*N* = 46)*P* \< 0.001*P* = 0.288*P* \< 0.001Hematocrit (L/L, mean ± SD)0.38 ± 0.030.37 ± 0.030.37 ± 0.04*P* = 0.795*P* = 0.164*P* = 0.175Hemoglobin (g/L, mean ± SD)123.40 ± 9.36123.91 ± 12.03119.83 ± 14.84*P* = 0.857*P* = 0.227*P* = 0.102Platelet (10\^9/L, mean ± SD)220.53 ± 40.22208.10 ± 58.23182.95 ± 66.72*P* = 0.588*P* = 0.011*P* = 0.154Fibrinogen (g/L, mean ± SD)4.06 ± 0.743.67 ± 0.883.88 ± 0.64*P* = 0.031*P* = 0.338*P* = 0.169D-Dimer (mg/L, medians and interquartile ranges)1.67 (1.16--2.82)1.81 (1.09--2.39)1.87 (1.27--2.66)*P* = 0.390*P* = 0.966*P* = 0.371Brain natriuretic peptide (pg/mL, medians and interquartile ranges)26.50 (17.25--65.50)78.50 (25.75--228.00)84 (32--186)*P* = 0.010*P* = 0.005*P* = 0.993FT3 (pg/mL, medians and interquartile ranges)3.56 (2.78--5.93)3.48 (2.82--4.62)4.32 (3.10--5.37)*P* = 0.659*P* = 0.621*P* = 0.105FT4 (ng/dL, medians and interquartile ranges)6.23 ± 1.066.21 ± 1.696.00 ± 1.89*P* = 1.000*P* = 0.885*P* = 0.925TSH (mIU/L, medians and interquartile ranges)2.92 ± 0.932.64 ± 1.432.62 ± 1.26*P* = 0.366*P* = 0.347*P* = 0.923Triglyceride (mmol/L, medians and interquartile ranges)1.95 ± 0.381.71 ± 0.821.77 ± 0.75*P* = 0.165*P* = 0.300*P* = 0.730Total cholesterol (mmol/L, mean ± SD)2.54 (2.24--2.68)2.49 (2.26--2.76)2.55 (2.35--2.70)*P* = 0.989*P* = 0.569*P* = 0.518Low density lipoprotein (mmol/L, mean ± SD)0.98 (0.90--1.06)0.95 (0.85--1.06)0.93 (0.83--1.05)*P* = 0.655*P* = 0.229*P* = 0.477High density lipoprotein (mmol/L, mean ± SD)2.32 (1.79--3.26)2.61 (1.63--4.20)2.18 (1.67--3.05)*P* = 0.748*P* = 0.534*P* = 0.433Rate of preterm birth (n%)7.1% (2/28)84.1% (37/44)15.6% (7/45)*P* \< 0.001*P* = 0.486*P* \< 0.001Rate of abortion (n%)02.1% (1/48)0NSNSNSRate of induced labor (n%)04.2% (2/48)0NSNSNSRate of fetal death (n%)02.1% (1/48)2.2% (1/46)NSNS*P* = 0.315Thyroid dysfunction (n%)60% (18/30)71.9% (41/57)56.3% (27/48)*P* = 0.258*P* = 0.744*P* = 0.094Hypothyroidism (n%)010.5% (6/57)4.2% (2/48)NSNS*P* = 0.162Subclinical hypothyroidism (n%)20% (6/30)15.8% (9/57)8.3% (4/48)*P* = 0.804*P* = 0.284*P* = 0.072FT3 under the lower limit (n%)6.7% (2/30)10.5% (6/57)2.1% (1/48)*P* = 0.514*P* = 0.680*P* = 0.072FT4 under the lower limit (n%)16.7% (5/30)19.3% (11/57)25% (12/48)*P* = 0.339*P* = 0.623*P* = 0.556FT3 and FT4 both under the lower limit (n%)6.7% (2/30)7.0% (4/57)10.4% (5/48)*P* = 0.909*P* = 1.000*P* = 1.000Hashimoto thyroiditis (n%)13.3% (4/30)8.8% (5/57)4.2% (2/48)*P* = 1.000*P* = 0.303*P* = 0.267hyperthyroidism (n%)03.5% (2/57)2.1% (1/48)NSNS*P* = 0.773A nominal 2-sided probability value \< 0.05 was considered to indicate statistical significance, and adjustments were made for multiple comparisons in chi-square test and Kruskal Wallis Test (*P*~adjust~ \< 0.017)*PIH* pregnant induced hypertension; *EPE* early onset preeclampsia; *LPE* late onset preeclampsia; *FT3* free triiodothyronine; *FT4* free thyroxine; *TSH* thyrotropic hormone

Associations between gestational hypertension disease, thyroid dysfunction and neonatal outcomes {#Sec10}
------------------------------------------------------------------------------------------------

The rates of preterm birth and low birth weight was significantly higher in the patients with thyroid dysfunction than those without (49.3% vs. 25%, *P* = 0.008; 45.1% vs. 27.1%, *P* = 0.047). In the study population, both the severity of gestational hypertension (OR = 4.360, 95%CI \[2.050, 9.271\], *P* \< 0.001) and thyroid dysfunction (OR = 3.011, 95%CI \[1.248, 7.262\], *P* = 0.014) were associated with a higher risk of preterm birth, while the onset time of preeclampsia (OR = 0.031, 95%CI \[0.009, 0.110\], *P* \< 0.001) was negatively associated with the risk of preterm birth. Similarly, both the severity of gestational hypertension (OR = 4.023, 95%CI \[1.933, 8.372\], *P* \< 0.001) and hypothyroidism (OR = 11.306, 95%CI \[1.040, 122.889\], *P* = 0.046) were associated with an increased risk of low birth weight, while the onset time of preeclampsia (OR = 0.097, 95%CI \[0.033, 0.282\], *P* \< 0.001) was negatively associated with the risk of low birth weight. Results of logistic regression analysis for thyroid dysfunction and fetal outcomes were summarized in Table [3](#Tab3){ref-type="table"}. Table 3Logistic regression results for the associations between gestational hypertension disease, thyroid dysfunction and neonatal outcomes (preterm birth and low birth weight)Characteristicspreterm birthlow birth weightUnadjustedAdjustedUnadjustedAdjustedseverity of gestational hypertension (PIH, MPE, SPE) OR4.9144.3604.1194.023 95% CI2.354--10.2552.050--9.2712.084--8.1441.933--8.372 *P* Value\< 0.001\< 0.001\< 0.001\< 0.001Onset time of gestational hypertension (EPE, LPE) OR0.0360.3310.11080.097 95% CI0.011--0.1120.009--0.1100.041--0.2830.033--0.282 P Value\< 0.001\< 0.001\< 0.001\< 0.001Thyroid dysfunction OR2.8293.0112.1402.187 95% CI1.261--6.3461.248--7.2620.969--4.7260.919--5.208 P Value0.0120.0140.0600.077Hypothyroidism OR6.1823.37315.45511.306 95% CI0.993--38.4780.411--33.8931.625--146.9731.040--122.889 P Value0.0510.2420.0170.046Both FT3 and FT4 under the lower limit OR1.4481.4961.4931.531 95% CI1.064--1.9711.000--2.2371.103--2.0211.049--2.234 P Value0.0190.2420.0090.027Adjusted for age, gestational history, menstrual cycle, family history, and history of gestational hypertension*PIH* pregnant induced hypertension; *MPE* mild preeclampsia; *SPE* severe preeclampsia; *EPE* early onset preeclampsia; *LPE* late onset preeclampsia; *FT3* free triiodothyronine; *FT4* free thyroxine; *TSH* thyrotropic hormone

Discussion {#Sec11}
==========

In this retrospective case-control study, we found that patients with severe preeclampsia, early onset preeclampsia or thyroid dysfunction had higher risk of adverse maternal and fetal outcomes such as preterm birth and low neonatal birth weight. Our data show that the rates of preterm birth and thyroid dysfunction were the highest in the patients with EPE. Although we could not find significant differences between EPE and PIH groups in the rates of thyroid dysfunction (71.9% vs. 56.7%), giving more emphasis on the thyroid hormones in those patients with EPE might reduce some adverse maternal and fetal outcomes.

Preeclampsia is one of the major causes of maternal and perinatal death \[[@CR33]\]. To better manage this disease, we need to improve our knowledge to better identify patients with preeclampsia at increased risk for adverse outcomes. In this study, most maternal adverse outcomes happened in patients with SPE or EPE. We found that BNP was significantly higher in these two groups which was in accordance with the symptoms. However, we did not find any difference among these groups in blood lipids. Most previous studies have found that thyroid dysfunction occurs more frequently in women with preeclampsia than in normal pregnant women \[[@CR8], [@CR18]\], and is associated with many adverse pregnant outcomes such as spontaneous abortion, intrauterine fetal death, preterm birth, and low birth weight etc. \[[@CR3], [@CR7], [@CR11]--[@CR13], [@CR16], [@CR17], [@CR34]\] Our results are in accordance with these previous studies.

Hypothyroidism has been shown to have various vascular pathogenic effects, including endothelial cell dysfunction \[[@CR35]\] which is also a pathophysiological basis of gestational hypertension. A study including 16,364 singleton births hypothyroid mothers in Finland found that maternal hypothyroidism was associated with higher risks of gestational hypertension (OR = 1.20, 95% CI \[1.10--1.30\]), severe preeclampsia (OR = 1.38, 95% CI \[1.15--1.65\]), preterm births (OR = 1.25, 95% CI \[1.16--1.34\]), major congenital anomalies (OR = 1.14, 95%CI \[1.06--1.22\]), and neonatal intensive care unit admission (OR = 1.23, 95% CI \[1.17--1.29\]) \[[@CR36]\]. Surks et al. \[[@CR37]\] showed that increased maternal serum TSH (higher than 10 mIU/L) was associated with increased risk of stillbirth. A study including 25,756 women conducted by Casey and colleagues \[[@CR3]\] revealed that subclinical hypothyroidism in pregnancies was associated with a 3-fold increased risk of placental abruption (relative risk 3.0, 95% CI \[1.1--8.2\]). The risk of preterm birth was almost 2-fold higher in women with subclinical hypothyroidism than in those without (relative risk, 1.8, 95% CI \[1.1--2.9\]). Another study showed that the incidence of premature birth, low birth weight and neonatal asphyxia was significantly higher in pregnant women with hyperthyroidism than that in normal pregnant women \[[@CR38]\]. In our study, only two types of thyroid dysfunction - i.e. hypothyroidism and FT3 and FT4 both below the normal lower limit - were found to be significantly associated with increased risk of low neonatal birth weight. The rate of hyperthyroidism was rare in this population. It might be due to the small sample size of our study or the racial differences of different studies.

Many studies focused only on the first trimester \[[@CR9], [@CR19], [@CR25], [@CR39], [@CR40]\], and did not include all preeclampsia types \[[@CR41]\]. The present study investigated thyroid hormones of women with gestational hypertension in the second half trimester and compared various types of preeclampsia according to the severity and the gestational age. Our results were also in consistency with other studies in the second half trimester. A study including 6031 mothers showed that after normalization of the thyroid hormones with appropriate treatment in women developing hypothyroidism in the first trimester, there was no significant difference in the risk of developing preeclampsia compared with the normal pregnant women. However, if the women developed hypothyroidism in the third trimester, they still had a 2.18-fold higher risk of developing preeclampsia \[[@CR34]\]. A prospective study in China \[[@CR42]\] including 3398 pregnant women found that isolated maternal hypothyroxinemia (IMH) in the first trimester did not increase the risk of adverse outcomes irrespective of whether women received L-thyroxine treatment or not. However, IMH identified in the second trimester was associated with a significantly increased risk of adverse pregnancy outcomes. The results suggest that thyroid function follow-up during the second trimester is necessary, even if thyroid function is normal during the first trimester. Therefore, comprehensive monitoring of thyroid hormones throughout the whole pregnancy and early treatment are very important to reduce the risk of preterm birth and low birth weight. Consequently, the rate of neonatal intensive care unit will be decreased and the burden to the family and the society will also be reduced. Thus, it might be helpful to test thyroid hormones in women with preeclampsia in all three stages, treatment should be initiated as early as possible by thyroid dysfunction to avoid adverse pregnant outcomes.

Our study had a few limitations. First, as a retrospective investigation, we could only analyze variables that were appropriately documented, and we were not able to investigate those patients without results of thyroid hormones. Second, this was a single center study with a small sample size, so the sensitivity and specificity of results were not quite satisfactory. With the popularity of thyroid function tests, we will get more accurate and precise data in China. Due to the retrospective design and the small size of our study, currently we cannot determine whether thyroid dysfunction in the first half trimester or in the second half trimester have a greater effect on maternal and fetal pregnancy outcomes. Data are also lacking regarding whether the treatment is obligatory for patients with FT3 and FT4 both under the lower limit but normal TSH to prevent adverse neonatal outcomes. Certainly, further studies are needed to widen our understanding on thyroid dysfunction and neonatal outcomes.

Conclusions {#Sec12}
===========

Our data indicate that more severe and early onset preeclampsia, as well as thyroid dysfunction were associated with significantly increased risk of neonatal adverse outcomes such as preterm birth and low neonatal birth weight. Therefore, monitoring thyroid hormones in women with preeclampsia might help to predict and consequently reduce the adverse neonatal outcomes.

BNP

:   Brain natriuretic peptide

EPE

:   Early onset preeclampsia

FGR

:   Fetal growth restriction

FT3

:   Free triiodothyronine

FT4

:   Serum free thyroxine

IMH

:   Isolated maternal hypothyroxinemia

LPE

:   Late onset preeclampsia

MPE

:   Mild preeclampsia

PIH

:   Pregnant induced hypertension

SPE

:   Severe preeclampsia

TPOAb

:   Serum thyroid peroxidase antibody

TSH

:   Serum thyrotropic hormone
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